TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from BerGenBio ASA ( (BRRGF) ).
BerGenBio ASA announced a delay in the timeline for its planned merger with Oncoinvent ASA and BerGenBio Norge AS, as well as the associated rights issue. The merger is expected to be completed by the end of October 2025, with trading of the combined company’s shares commencing shortly thereafter. The rights issue, which offers preferential subscription rights to existing shareholders, is anticipated to start in mid-November 2025. These developments are crucial for BerGenBio’s strategic growth, potentially enhancing its market position and providing new opportunities for stakeholders.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA operates in the biotechnology industry, focusing on developing innovative therapies for aggressive diseases, particularly cancer. The company is engaged in research and development to bring new treatments to market, often collaborating with other entities to enhance its offerings.
Average Trading Volume: 201,797
Current Market Cap: NOK43.93M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.